rawfin.tv
Merck's Capvaxive Vaccine Gains US Approval for High-Risk Children, Teens
RegulationstocksAI Generated

Merck's Capvaxive Vaccine Gains US Approval for High-Risk Children, Teens

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

Merck & Co.'s Capvaxive pneumococcal vaccine has received expanded approval from U.S. health regulators for use in high-risk children and teenagers. This regulatory milestone is expected to broaden the market for the pharmaceutical giant's product.

MRKPharmaceuticalsVaccineFDA ApprovalHealthcare

Related Articles

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

stocks
EQT to Acquire Cleanaway Waste for $6.5 Billion

EQT to Acquire Cleanaway Waste for $6.5 Billion

stocks
S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

stocks
US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

stocks